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AbstrACt
Objectives the aim of this study was to adapt the 
Systemic Sclerosis Quality of Life Questionnaire (SScQoL) 
into six European cultures and validate it as a common 
measure of quality of life in systemic sclerosis (SSc).
Methods this was a seven-country (Germany, 
France, Italy, poland, Spain, Sweden and UK) cross-
sectional study. A forward–backward translation 
process was used to adapt the English SScQoL into 
target languages. SScQoL was completed by patients 
with SSc, then data were validated against the rasch 
model. to correct local response dependency, items 
were grouped into the following subscales: function, 
emotion, sleep, social and pain and reanalysed for 
fit to the model, unidimensionality and cross-cultural 
equivalence.
results the adaptation of the SScQoL was seamless in 
all countries except Germany. Cross-cultural validation 
included 1080 patients with a mean age 58.0 years 
(Sd 13.9) and 87% were women. Local dependency 
was evident in individual country data. Grouping items 
into testlets corrected the local dependency in most 
country specific data. Fit to the model, reliability and 
unidimensionality was achieved in six-country data after 
cross-cultural adjustment for Italy in the social subscale. 
the SScQoL was then calibrated into an interval level 
scale.
Conclusion the individual SScQoL items have 
translated well into five languages and overall, the scale 
maintained its construct validity, working well as a five-
subscale questionnaire. Measures of quality of life in SSc 
can be directly compared across five countries (France, 
poland Spain, Sweden and UK). data from Italy are 
also comparable with the other five countries although 
require an adjustment.
IntrOduCtIOn
Systemic sclerosis (SSc) is a heterogeneous connec-
tive tissue disease characterised by vasculopathy, 
immune activation and fibrosis.1–3 The multisystem 
involvement in the disease has severe physical and 
psychosocial impact affecting the patients’ quality 
of life (QoL). QoL is a complex interaction between 
the ways in which people perceive their health and 
how it relates to other aspects of their lives that are 
less directly health-specific.
Several tools have been used in different studies to 
capture QoL in people with SSc, such as the SF-36 
and the EuroQol 5-Domain health questionnaire,4–6 
however, these tools are not disease-specific and can 
be less sensitive to the more directly disease-related 
factors. To capture the true psychosocial impact of 
the disease, a needs-based disease-specific QoL is 
the gold standard. The Systemic Sclerosis Quality of 
Life Questionnaire (SScQoL), developed by Reay7 
and translated into six languages in this paper, was 
developed according to this principle. The SScQoL 
tool measures the disease impact on health and well-
being, and has been developed using a needs-based 
quality of life model, which is based on the under-
standing that individuals are driven or motivated by 
their needs and that life gains its quality from the 
ability and capacity of individuals to satisfy their 
needs.8 9
During its development, the original SScQoL7 was 
subject to strict principles of item response theory 
to ensure the highest quality measure of needs-
based patient-reported QoL reporting in people 
with SSc. The SScQoL joins a stable of measures 
including the Rheumatoid Arthritis Quality of 
Life,10 Osteoarthritis Quality of Life11 and Anky-
losing Spondylitis Quality of Life12 developed at the 
University of Leeds and forming the cornerstone of 
patient-reported outcome measurement (PROM) in 
many rheumatological conditions.
The SScQoL is a self-completed questionnaire 
comprising 29 questions exploring the impact of 
SSc on health and well-being, covering four themes 
identified by patients with SSc: emotion, physical 
adaptation, impact on/with others and impact 
on self. It takes the patient approximately 5 mins 
to complete and provides quantitative data that 
enables the health professional involved to accu-
rately evaluate the impact of SSc on an individual 
patient or groups of people with the disease. Due 
to its robust validation, the SScQoL can also be 
used with confidence as a research tool to eval-
uate pharmacological and non-pharmacological 
interventions.
Initial development and testing demonstrated 
the reliability, validity and the patient acceptance 
of the instrument and the original English language 
version of the tool has been subjected to Rasch 
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Analysis to ensure its construct validity, unidimensionality and 
absence of differential item functioning.7
the relevance of a common measure
SSc is considered a rare disease due to its prevalence (82 per 
1 000 000 adjusted for the UK population).13 The small numbers 
of people affected by SSc causes methodological problems, 
particularly when developing research studies requiring large 
sample sizes. To overcome these problems, there is a need for 
multicentre and international studies, using common outcome 
measures, which have demonstrable cross-cultural relevance 
and measurement equivalence, which in turn allow researchers 
to obtain reliable results that are comparable across countries. 
In addition, the existing European collaborations and networks 
such as EUSTAR and EUSHNet can employ a common measure 
prospectively in a systematic way, such that the networks and 
patients in the countries involved can benefit from the consis-
tency provided by a cross-culturally valid measure.
The objectives of this study therefore were to: (i) translate 
and adapt the SScQoL for use in Germany, France, Italy, Poland, 
Spain and Sweden; (ii) undertake a cross-cultural validation of 
the SScQoL for use in these countries; (iii) calibrate a common 
scale that is comparable across countries and (iv) ultimately 
incorporate the translated and validated version of the SScQoL 
into the EUSTAR MEDS database to create a common minimum 
dataset for PROMS in SSc research in Europe. This paper reports 
the results of the objectives (i) through (iii).
MetHOds
study design
This was a multicentre cross-sectional analytic study involving 
seven European countries; Germany, France, Italy, Poland, 
Spain, Sweden and the UK. The study involved two phases (i) 
cross-cultural adaptation and (ii) cross-cultural validation.
Cross-cultural adaptation phase
The English SScQoL was adapted into six languages using the 
well-established process of cross-cultural adaptation of self-re-
port measures.14 The aim of cross-cultural adaptation is to ensure 
conceptual equivalence between original and target versions 
of a questionnaire. This process involved the following stages 
for each of the collaborating centres: (i) the original (English) 
version was translated into the target language by two transla-
tors working independently; (ii) the translations were compared 
and any inconsistencies resolved; (iii) the translated tools were 
then translated back into English by a translator not involved 
in stage one; (iv) once satisfactory translations had evolved, all 
four versions were reviewed by an expert committee and any 
outstanding inconsistencies were resolved by discussion and (v) 
the adapted questionnaires were completed by 30 patients with 
SSc in each of the collaborating centres.
Cross-cultural validation phase
The aim of this stage was to ensure measurement equivalence 
of the SScQoL, to enable common measurement across the 
seven countries. During this phase, the translated question-
naires were completed by 100–270 patients (in each country) 
by either postal or site survey. Participants were native 
speakers of the target languages except in Sweden where seven 
participants were non-native but all had lived in Sweden for 
several years and had a good ability to speak and read Swedish. 
The data from the new SScQoL were then subjected to Rasch 
analysis, which involved testing the construct validity of each 
translated tool, internal consistency and the cross-cultural 
invariance of the tool across all the seven countries. Finally, 
the common measure was calibrated, which takes account of 
cultural differences and, if successful, provides for pooling 
and comparison of measurements across the various culturally 
adapted versions.
Patients
Each centre recruited a convenience sample of patients from 
rheumatology outpatient clinics and/or patient databases. The 
inclusion criteria were: (i) consultant diagnosis of SSc according 
to ARA/ACR 1980 criteria,15 (ii) aged ≥18 years and (iii) will-
ingness and ability to complete and return a questionnaire. 
The only exclusion criterion was an inability to understand or 
complete the written questionnaire. Participation in the study 
was voluntary and each of the collaborating centres followed 
ethical procedures applicable to their respective countries 
before recruiting patients. Local investigators in each collabo-
rating country handled all patients’ (interview) data collected 
during the cross-cultural adaptation phase. The data collected 
during the validation phase in each country was then sent to 
the University of Leeds for psychometric testing using Rasch 
models. Data transferred were limited to anonymised SScQoL 
data containing patient’s age and gender information.
data analysis
The validation data were analysed using RUMM2030 software 
(RUMM Laboratory, Perth, Western Australia). First, each 
country-specific dataset was tested for fit to the Rasch model. 
Fit to the Rasch model implies construct validity, reliability, 
unidimensionality and statistical sufficiency of the total score 
from the scale.16–19 Model fit was determined by item–person 
interaction statistics which compare the difference between 
observed responses and values expected by the model (stan-
dardised residuals). The following statistics suggest fit to the 
model: (i) item–person interaction statistics, distributed as a 
Z statistic with a mean of 0 and SD of 1; (ii) item χ2 statistic 
(comparing the difference between observed and expected 
values) with a non-significant probability—several χ 2 are 
computed for each item across groups, therefore Bonferroni 
adjustment is required to avoid type I errors due to multiple 
testing;20 (iii) item–trait interaction statistic reported as a 
non-significant χ2 probability, reflecting the invariance of the 
SScQoL to different levels of quality of life.
An estimate of internal consistency (reliability) was deter-
mined by person separation index (PSI), which represents 
the ability of the SScQoL to distinguish between people with 
different levels of reported quality of life. A value of 0.7 is 
required for group use.19
Although fit to Rasch model implies unidimensionality of 
the scale, further tests were carried out to confirm the assump-
tion of local independence of items,21 unidimensionality 
and differential item functioning. The Rasch model assumes 
that each item independently contributes to the underlying 
construct, no significant item–item residual correlations are 
expected therefore, after contribution to the construct is 
removed. Where significant item–item residual correlations 
were identified (through residual correlation matrices), these 
locally dependent items were grouped and treated as a unit, 
referred to as a ‘testlet’, which represent a subscale. Two inves-
tigators (MN and ACR) grouped the items by consensus into 
the following testlets: function, emotion, sleep, social and 
pain, which in turn map onto the International Classification 
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of Functioning, Disability and Health model. The testlets were 
treated as ‘superitems’ in the subsequent analyses.
Unidimensionality was confirmed using the principal 
component analysis and t-test-based method proposed by 
Smith.22 Two sets of items hypothesised to represent low 
levels and high levels of quality of life were defined, based 
on the correlation between items and the first residual factor. 
An independent t-test was then used to compare the differ-
ence in these estimates for each person. Unidimensionality 
was confirmed if ≤5% of the t-tests were significant or if 
lower bound of a binomial 95% CI of the observed proportion 
overlapped 5%.19 22
Cross-cultural (measurement) equivalence was tested using 
the differential item functioning (DIF) analysis feature in-built 
into RUMM2030. This is based on a two-way analysis of vari-
ance (ANOVA) of residuals across each level of person factor 
(in this case, culture) and across different levels of trait (in this 
case, quality of life). Presence of uniform DIF was suggested if 
the P value of the main effects (culture) was significant. This 
test flags the presence of significant DIF in the pooled datasets 
(significant difference between two or more group means) but 
does not specify where the difference lies. The post hoc Tukey 
test which performs a pairwise comparison of means was used 
to explore DIF patterns and identify which country-specific 
dataset(s) exhibited the DIF. Once identified, the testlet affected 
by cross-cultural DIF was ‘split’ into two, to provide a cultur-
ally specific (emic) testlet for the country exhibiting the DIF and 
a culturally general (etic) testlet for the rest of the countries. 
Once the DIF-affected testlet was split, the pooled data were 
reanalysed to assess fit to the model. This method of post hoc 
DIF analysis is detailed elsewhere.23–26
When fit to the model was established, the raw SScQoL scores 
were mapped against the corresponding Rasch-transformed 
(logit-based) scores and were linearly transformed to calibrate 
an interval scale of the same range. This allows for transforma-
tion of raw scores to interval scaling.27 The raw-to-linear score 
conversion table provided the adjustment for the cross-cultural 
difference via the split testlet.23–25 27
results
Cross-cultural adaptation
The adaptation of the SScQoL into European languages was 
largely seamless except for the German dataset in which patients 
had reported problems in providing strictly dichotomous ‘yes/
no’ responses on the following 10 items: (Q4) my condition 
makes me angry; (Q9) my condition means I have disturbed 
sleep; (Q11) it has affected the health of people around me; 
(Q12) my hands do not work as well as they did; (Q13) it puts 
a strain on my personal relationships; (Q15) any sort of activity 
is difficult; (Q19) I cannot cope at all; (Q20) sleeping badly has 
affected me a lot; (Q25) I struggle to wash myself as I would like; 
(Q27) I feel helpless and (Q29) I miss being able to sort things 
out. In Sweden, patients reported problems with two items: 
with regard to (Q5) ‘I get upset when I cannot do things’ they 
preferred using ‘disappointed’ or ‘sad’ instead of ‘upset’ and for 
(Q10) ‘it has affected me a lot socially’, participants suggested to 
remove ‘a lot’.
For the Spanish translation, in item Q27 (I feel helpless), 
the translators had difficulties in finding a word that captured 
the English meaning of ‘helpless’ (‘impotencia’ in Spanish). A 
consensus was reached among the translators that the Spanish 
word ‘impotencia’ which means ‘impotence’ in English had the 
closest meaning to ‘helpless/powerlessness’. Since ‘impotencia’ 
also means sexual dysfunction, translators recommended that 
clarification should be provided to the patients when the ques-
tionnaire is issued to avoid confusion.
Validation
Patient characteristics
In total, 1080 patients were recruited and their age and gender 
distribution parameters are summarised in table 1.
Fit to the Rasch model
Table 2 presents item–person fit statistics reliability and unidi-
mensionality of the SScQoL for individual countries’ datasets. 
The initial analyses of the 29-item scales for each country (based 
on individual items, table 2A) suggest an initial lack of fit for the 
German, Italian, Polish and Swedish data (values representing a 
perfect fit to the model are given in the lowest row of table 2). 
Individual item fit statistics for each country are provided in 
the online supplementary table S1 . Assessment of the residual 
correlation matrix revealed significant local dependence (item–
item residual correlation >0.3), which was largely responsible 
for the lack of fit.
The 29 items of the full scale were the mapped by consensus 
by the project leaders (MN and ACR) onto five domains corre-
sponding to the components of the International Classification 
of Functioning, Disability and Health model: function (activity 
limitation), emotional (personal factors), sleep (personal 
factors), social (participation restrictions) and pain (impairment) 
(see table 3).
Using the 5-testlet model, the responses for six countries 
(France, Italy, Poland, Spain, Sweden and the UK) showed a good 
fit to the Rasch model confirming construct validity, reliability 
and unidimensionality in the country-specific data (see table 2B). 
The German data continued to exhibit significant deviations 
from the Rasch model (item residual mean −0.698, SD 2.795, 
item–trait interaction χ2 P<0.001). The datasets for the six 
countries that had evidence of fit to the Rasch model (France, 
Italy, Poland, Spain, Sweden and the UK) were combined in a 
pooled analysis and the results suggested that each testlet had 
an acceptable fit to the Rasch model (see table 2B). However, 
the item–trait (testlet–trait) interaction χ2 statistic for the pooled 
dataset continued to display significant deviation from the 
model expectations (χ2=63.909, df=45, P=0.034) suggesting 
lack of invariance (presence of DIF) across different levels of 
quality of life.
Cross-cultural invariance
DIF analysis highlighted a significant cross-cultural bias in the 
social subscale (table 4). Post hoc Tukey analysis revealed that 
the DIF was displayed by the Italian dataset. The social subscale 
table 1 Sample characteristics by country
Country
sample Gender Age
n M (%) F (%) Mean sd
UK 121 15 (12.40) 106 (87.60) 57.09 12.073
France 115 18 (15.65) 97 (84.35) 59.05 13.226
Italy 131 16 (12.31) 114 (87.69) 57.96 15.031
Sweden 102 9 (8.74) 94 (91.26) 60.01 12.332
Germany 274 27 (9.90) 239 (87.20) 60.84 10.569
Poland 231 33 (14.29) 198 (85.71) 55.85 12.552
Spain 106 19 (17.92) 87 (82.08) 54.84 13.971
Pooled 1080 137 (12.69) 943 (87.31) 57.95 13.894
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was therefore ‘split’ such that there was a social-etic subscale 
which is culturally general (for five countries—France, Poland, 
Spain, Sweden and the UK) and a social-emic subscale which 
was culturally specific to Italy. This split improved the overall fit 
statistics of the pooled data (see the online supplementary table 
S2). The subsequent item–trait χ2 statistic suggested adequate fit 
to the model (χ2=65.580, df=54, P=0.140) and the reliability 
remained good (PSI=0.841).
Calibrating an interval scale
Following DIF analysis and the adjustment for cross-cultural DIF, 
the raw scale scores were transformed into logit-based (interval 
level) scores for the five testlets, with an adjusted social subscale 
for Italy (see table 5).
dIsCussIOn
The original SScQoL was developed with patients to ensure it 
captures HRQoL aspects that are of interest to patients. Having 
satisfied the requirements of the Rasch model expectations, the 
tool has demonstrated validity, reliability and statistical suffi-
ciency.7 In this study, a new UK dataset was collected and the 
conclusions were consistent with those of the original devel-
opment study. Additionally, we have employed a standardised 
method of questionnaire adaptation into the European languages 
(and associated cultures), ensuring that the tool maintains a 
conceptual equivalence between the original and the adapted 
(translated) versions. Furthermore, in this analysis, we have 
transposed the concept of SScQoL into five subscale measures, 
where each item contributes to the subscale and the overall 
dimension. Therefore, the subscale score provides the estimate 
of quality of life specific for that domain (function, emotional, 
sleep and so on) and the total score provides a sufficient statistic 
for overall health-related quality of life in SSc.
Rasch analyses confirmed measurement equivalence between 
the English and all adapted versions except the German, where 
patients had found it difficult to complete some dichotomous 
items, indicating a preference for rating scales or having more 
options. This implies that for those patients, the dichotomous 
items, as presented, failed to capture the full range of their 
responses. As the SScQoL is a needs-based measure, failure of 
the tool to measure the full range of patient responses appears to 
have had an impact on the validity of the German version of the 
scale as reflected in the lack of fit to the model. Future work on 
this specific version will explore the wording and presentation 
of the root questions, as well as the potential for, and impact of 
making available trichotomous or higher level response options.
All translations, except the German version, demonstrated 
sufficient validity and fit to the Rasch model to support their use 
for single-country studies and within-country comparisons. The 
current analysis confirmed the unidimensionality and measure-
ment equivalence in five of the six countries when evaluated across 
five domains. Good internal validity and reliability ensures that 
clinicians (and patients) can use the tool with confidence when 
evaluating HRQoL at person and at population levels. Using the 
SScQoL alongside other outcome measures ensures that quality of 
life is being taken into account when providing care.
Since comparable scales are now available for six of the seven 
languages/cultures, employing the logit-based transformed scores 
as summarised in table 4 enables accurate estimation of SScQoL as 
an interval level measure, as well as comparability across cultures. 
table 2 Item–person fit statistics, reliability and unidimensionality of the SScQoL (country-specific data)
Country
Item fit residual Person fit residual
Item–trait
χ2 interaction
Person separation 
reliability unidimensionality test*
Mean sd Mean sd Value (dF) P value PsI n
Proportion of independent 
t-tests (binomial 95% CI)
A: Analysis of the SScQoL with individual 29 items
  UK −0.232 1.043 −0.233 0.680 48.932 (29) 0.012 0.919 112 0.099 (0.060 to 0.138)
  France −0.291 1.048 −0.271 0.855 34.868 (29) 0.209 0.893 111 0.087 (0.047 to 0.127)
  Germany −0.704 2.034 −0.484 1.456 398 (116) <0.001 0.881 263 0.063 (0.028 to 0.099)
  Italy −0.205 1.051 −0.285 0.756 88.662 (58) 0.006 0.890 125 0.053 (0.016 to 0.091)
  Poland −0.520 1.380 −0.342 0.950 187.494 (116) <0.001 0.902 221 0.099 (0.060 to 0.138)
  Spain −0.166 0.751 −0.220 0.654 42.439 (29) 0.051 0.906 95 0.075 (0.033 to 0.116)
  Sweden −0.264 0.910 −0.273 0.728 60.886 (29) <0.001 0.892 101 0.068 (0.026 to 0.110)
B: Analysis of the SScQoL as a 5-testlet scale
  UK 0.016 1.535 −0.288 0.848 4.992 (5) 0.417 0.896 109 0.050 (0.011 to 0.088)
  France 0.020 1.380 −0.280 0.895 2.368 (5) 0.796 0.826 106 0.028 (-0.013 to 0.068)
  Germany −0.698 2.795 −0.285 0.873 61.952 (20) <0.001 0.852 263 0.030 (-0.013 to 0.073)
  Italy −0.137 1.888 −0.315 0.831 4.281 (5) 0.510 0.818 125 0.038 (0.001 to 0.075)
  Poland −0.348 2.139 −0.308 0.966 22.450 (15) 0.096 0.853 221 0.043 (0.015 to 0.071)
  Spain −0.265 1.346 −0.221 0.711 11.430 (5) 0.043 0.846 92 0.018 (-0.023 to 0.060)
  Sweden −0.136 0.793 −0.253 0.819 25.665 (44) 0.988 0.813 95 0.030 (-0.013 to 0.073)
  Perfect fit 0 1 0 1 >0.05 >0.70 ≤0.05 or lower-bound 95%CI≤0.05
P value, χ2 probability, where >0.05 (>0.01 for Bonferroni correction) suggest adequate fit to the model.
*Unidimensionality was deemed supported if ≤5% (0.05) of independent t-tests were significant or if lower bound of a binomial 95% CI of the observed proportion overlapped 
5% (0.05).
DF, degree of freedom; PSI, Person Separation Index (internal consistency) reliability; SScQoL, Systemic Sclerosis Quality of Life Questionnaire.
table 3 Testlets formed by grouping items
testlet number of items Items
Function 6 1, 12, 14, 15, 22 and 25
Emotional 13 2, 3, 4, 5, 6, 7, 8, 17, 18, 19, 24, 27 and 29
Sleep 2 9 and 20
Social 6 10, 11, 13, 16, 21 and 23
Pain 2 26 and 28
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This means that it is now possible to pool large datasets across 
countries and/or to develop collaborative projects using a common 
measure of SScQoL. It is recommended therefore that future 
studies report subscale scores routinely, as well as reporting single-
scale scores, to facilitate comparison and data pooling across coun-
tries. As further work will be required to explore how the German 
SScQoL works in other samples, caution will be required until this 
work is complete when comparing between German scores and 
scores from other countries.
This study sets out to establish a common measure of QoL in 
SSc across seven countries. The study has two main limitations. 
First, the cross-cultural validation of the SScQoL in Germany 
did not work as expected. Two subsets of data were collected for 
this analysis and these datasets, both individually and in pooled 
table 4 Results of DIF analysis in pooled data (France, Italy, Poland, Spain, Sweden and UK)
testlet
Main effects: country (uniform dIF) Interaction effects: class interval by country (non-uniform dIF)
Mean square F-statistic degrees of freedom P value* Mean square F-statistic degrees of freedom P value*
Function 1.736 2.711 5 0.030 1.033 1.613 36 0.015
Emotional 1.777 3.297 5 0.011 0.574 1.065 36 0.371
Sleep 3.832 3.264 5 0.012 0.961 0.818 36 0.766
Social 9.603 15.839 5 <0.001 0.706 1.165 36 0.240
Pain 1.627 1.680 5 0.153 0.978 1.010 36 0.455
*Significant Bonferroni adjusted P value ≤0.003 suggest presence of uniform DIF.
DIF, differential item functioning.
table 5 Conversion table for raw-to-linear (Rasch transformed) scores with cross-cultural adjustment
raw scores
(yes=1, no=0)
Function
(all) 
emotional
(all) 
sleep
(all)
social
(Italy) 
social
(others) 
Pain
(all) 
total
 (Italy) 
total
(others) 
0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
1.0 1.3 1.6 1.0 0.8 1.6 1.0 2.9 3.6
2.0 2.4 2.8 2.0 1.4 2.6 2.0 4.8 6.0
3.0 3.1 3.7 1.8 3.3 6.0 7.5
4.0 3.8 4.5 2.4 3.9 6.9 8.6
5.0 4.8 5.2 3.7 4.7 7.7 9.6
6.0 6.0 5.9 6.0 6.0 8.3 10.3
7.0 6.6 8.9 11.0
8.0 7.3 9.4 11.6
9.0 8.0 9.9 12.2
10.0 8.9 10.3 12.8
11.0 9.9 10.8 13.3
12.0 11.2 11.2 13.8
13.0 13.0 11.6 14.3
14.0 12.1 14.8
15.0 12.5 15.3
16.0 12.9 15.8
17.0 13.4 16.3
18.0 13.9 16.8
19.0 14.3 17.3
20.0 14.8 17.8
21.0 15.3 18.4
22.0 15.9 19.0
23.0 16.5 19.7
24.0 17.1 20.4
25.0 18.0 21.3
26.0 19.0 22.4
27.0 20.6 23.8
28.0 23.6 25.9
29.0 29.0 29.0
The SScQoL has dichotomous yes/no responses, coded as 1 (yes) and 0 (no), yielding a scoring range 0–6 for the function subscale, 0–13 for the emotional subscale, and so on. 
The scores obtained from the patient are the raw scores and these must be converted to linear scores using the conversion chart. For example, if a patient has a raw score of 
2 on the functional subscale, this will be transformed to 2.4, if the patient has a raw scores of 3 on the emotional subscale this will transformed to 3.7, and so on in the other 
subscales. The social subscale is split, with transformed scores for Italy and the rest of the countries. If a patient from Italy has a raw score of 4 on the social subscale, this will be 
transformed to 2.4, but a raw score of 4 from patients in other countries will be transformed to 3.9. Adding up all the transformed subscale scores gives the total SScQoL score 
which is a comparable estimate of the patient’s quality of life (range 0–29), higher scores indicating a worse quality of life.
Others=France, Poland, Spain, Sweden and the UK.
SScQoL, Systemic Sclerosis Quality of Life Questionnaire. 
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form, showed lack of fit the model. Further work is required to 
explore different ways of formatting the items in such a way that 
a full range of patient responses will be better captured. Second, 
ethics committees in some countries permitted collecting only 
basic demographic details (age and gender) in addition to the 
SScQoL items, and this may have limited the factors or subgroups 
being tested for invariance. Third, being a cross-sectional study, 
this study did not assess the sensitivity to change of the adapted 
versions. Sensitivity to change was established for the original 
(English) version, and it is expected that the adapted versions 
will also demonstrate this. Further research will be required to 
determine the minimal clinically important difference to support 
measurement of the impact or of treatments on the quality of 
life in people with SSc. As result of the successful cross-cultural 
validation of the SScQoL into six different European countries, 
we recommend for this tool to be translated into more European 
languages and to be adopted as part of a core set of tools used 
in SSc observational and clinical trials studies. An implementa-
tion phase, working in combination with colleagues within the 
EUSTAR network and beyond, is required to move towards a 
more systematic approach to clinical data capture in SSc research.
COnClusIOn
The individual SScQoL items have translated well into five Euro-
pean languages and overall, the scale maintained its construct 
validity, working well as a five-subscale questionnaire. Using the 
logit-based transformed scores, measures of quality of life in SSc 
can be directly compared across five countries (France, Poland, 
Spain, Sweden and UK). Data from Italy are also comparable 
with the other five countries using a separate adjusted scale, 
which sufficiently recalibrates the scores in the social subscale, so 
as to allow a valid comparison across countries. While compar-
ison between German scores and the other countries will need 
further testing, it is likely that this can be accomplished with some 
extra work and in the interim, this study has provided a common 
measure of quality of life in people with SSc across six European 
countries. Future work will be required to define the thresholds 
of health-related quality of life and clinically meaningful change 
in SSc and to further adapt the SScQoL into a wider range of 
languages and cultural settings. Different versions of the SScQoL 
can be obtained at: https:// doi. org/ 10. 5518/ 325.28
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